论文部分内容阅读
目的分析利格列汀治疗老年2型糖尿病患者的临床疗效。方法选取86例应用其他类型降糖药物至少2个月血糖控制不佳且合并多种慢性疾病的老年2型糖尿病患者,给予联合利格列汀治疗24周,观察治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、肝功能[包括丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)]、肾功能[包括血尿素氮(BUN)、血肌酐(SCr)、尿白蛋白肌酐比值(UACR)]、血淀粉酶(AMS)、稳态模型胰岛素岛素抵抗指数(HOMA-IR)和胰岛β细胞功能指数(HOMA-β)指标变化。结果治疗后患者FPG、2 h PG、Hb A1c、HOMA-IR均较治疗前显著下降,而HOMA-β明显高于治疗前水平,差异有统计学意义(P<0.05),ALT、AST、ALP、BUN、SCr、UACR、AMS治疗前后比较差异均未见统计学意义(P>0.05)。结论利格列汀联合其他降糖药物治疗老年2型糖尿病患者能有效降低患者血糖水平,对肝肾功能不全患者无需调整剂量,并且安全性高。
Objective To analyze the clinical efficacy of linagliptin in the treatment of elderly type 2 diabetic patients. Methods Eighty-six elderly patients with type 2 diabetes mellitus with poorly controlled blood glucose control and at least 2 months of other types of hypoglycemic agents were treated with combination of linagliptin for 24 weeks. Fasting plasma glucose (FPG) Postprandial blood glucose (2 h PG), Hb A1c, liver function [including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) ], Renal function [including BUN, SCr, UACR], blood amylase (AMS), homeostasis model insulin resistance index (HOMA-IR) Islet β cell function index (HOMA-β) index changes. Results The levels of FPG, 2 h PG, Hb A1c and HOMA-IR in patients after treatment were significantly lower than those before treatment, while HOMA-β was significantly higher than that before treatment, the difference was statistically significant (P <0.05) , BUN, SCr, UACR, AMS no significant difference before and after treatment (P> 0.05). Conclusion Linagliptin combined with other antidiabetic drugs in elderly patients with type 2 diabetes can effectively reduce blood glucose levels in patients with liver and kidney dysfunction without dose adjustment and high safety.